Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROVAE: Ansuvimab and Ervebo for Ebola Post-exposure Prophylaxis
NCT04822376Phase 2Unknown
- Sponsor
- ANRS
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ansuvimab in Ebola virus disease (EVD), sponsored by ANRS. Status: unknown.
02
Drugs
ansuvimab
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT04822376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822376.